Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07622966 · ClinicalTrials.gov registry record · NA
Effect of Osteopathic Manipulation on Circulating Immune Markers
A NA study, sponsored by Edward Via Virginia College of Osteopathic Medicine.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT07622966: Completed NA study, sponsored by Edward Via Virginia College of Osteopathic Medicine.
NCT07622966 is a NA study that has completed, run by Edward Via Virginia College of Osteopathic Medicine. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07622966, a NA study, has completed, sponsored by Edward Via Virginia College of Osteopathic Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if osteopathic manipulative treatment (OMT) changes levels of immune markers in healthy volunteers. The main questions it aims to answer are: Does OMT change numbers of white blood cells or antibodies? Does OMT change levels of cytokines? Researchers will compare volunteers treated with OMT to volunteers undergoing sham treatment to see if OMT changes levels of immune markers. Participants will: * complete a survey about their medical history to determine if they are healthy enough for OMT * have blood drawn * undergo either sham treatment or OMT * have blood drawn 30 minutes after treatment
Interventions
- OTHER Sham Comparator
- OTHER Osteopathic Manipulative Treatment (OMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2025-06-17 |
| Phase | NA |
What the finished NCT07622966 record still lists
NCT07622966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT07622966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07622966 about?
NCT07622966 is a clinical study titled "Effect of Osteopathic Manipulation on Circulating Immune Markers". The goal of this clinical trial is to learn if osteopathic manipulative treatment (OMT) changes levels of immune markers in healthy volunteers. The main questions it aims to answer are: Does OMT change numbers of white blood cells or antibodies? Does OMT change levels of cytokines? Researchers wil...
What is the current status of trial NCT07622966?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2025-01-10. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT07622966?
The interventions under investigation include: Sham Comparator (OTHER), Osteopathic Manipulative Treatment (OMT) (OTHER).
Who is sponsoring clinical trial NCT07622966?
This trial is sponsored by Edward Via Virginia College of Osteopathic Medicine, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07622966's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI